Welcome To 5th Microbiome Movement - Drug Development Summit
As the first microbiome-based therapeutic steps closer to market approval, the scientific community continue to demonstrate the functional role of the human microbiome as a novel source of therapeutic, biomarker and diagnostic development. Despite this progress, the vast potential to develop effective treatments that target the human microbiome is still limited by the complex challenges in developing them.
Part of the foremost conference series for microbiome researchers in industry, the 5th Microbiome Movement – Drug Development Europe 2021 will return to unite leading scientists from the biopharmaceutical and academic community to pursue the causal role of the microbiome in disease, and help create a new generation of microbiome-targeted therapeutics with predictable modes of action and consistent clinical outcomes.
Last year consisted of three days of case-studies, discussion and debates, around how industry and academic leaders are understanding microbiome functionality across key therapeutic modalities, leveraging big data platforms to deduce causality, and overcoming regulatory, clinical and manufacturing hurdles to further accelerate their pipeline across new disease targets.
Program Director & Co-Founder
Top 3 Reasons To Attend
- Save time and resources by learning how leading companies are overcoming critical translational hurdles to drive microbiome R&D into a therapeutic reality
- Gain an important market update on the progress of microbiome-based therapeutics to benchmark your progress
- Establish lasting connections by joining the foremost series of industry conference for microbiome researchers
Hear What Our Customers Say
"As a newcomer to the microbiome field, this conference provided an excellent overview.”
“It was a great conference to effectively learn the current trends in microbiome drug development around the world.”